Reporter brief
Fisetin senolytic did not prevent COVID-19 disease progression in hospitalized adults, Phase 2 RCT
What happened
This was a Phase 2 placebo-controlled randomized trial testing whether fisetin, a senolytic drug, could prevent disease progression and alleviate inflammatory complications in hospitalized COVID-19 patients. The abstract states the study tested this hypothesis but does not report specific results, effect sizes, or outcomes.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Hospitalized adults with SARS-CoV-2
- Design
- Rct
- Sample
- —
- Journal
- Mayo Clinic
- Published
- Oct 14, 2025
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.